Melanotan II: Tanning, Libido & Everything You Need to Know

How Melanotan II Works: The Melanocortin System

The Melanocortin Receptors

Melanotan II is a synthetic cyclic analog of alpha-melanocyte stimulating hormone (α-MSH), the body's natural signal for melanin production. It activates multiple melanocortin receptors:

This multi-receptor activation explains why MT-II produces diverse effects simultaneously. It is not a selective agent — it activates all accessible melanocortin receptors, producing a constellation of effects rather than a single targeted outcome.

The Tanning Mechanism

When MT-II activates MC1R on melanocytes (the pigment-producing cells in your skin), it triggers a signaling cascade:

1. MC1R activation → cyclic AMP increase
2. cAMP activates protein kinase A (PKA)
3. PKA phosphorylates CREB transcription factor
4. CREB drives expression of MITF (melanocyte master regulator)
5. MITF upregulates tyrosinase and related enzymes
6. Tyrosinase converts tyrosine → DOPA → dopaquinone → melanin
7. Melanin is packaged into melanosomes
8. Melanosomes are transferred to surrounding keratinocytes
9. Skin darkens as melanin accumulates in the epidermis

This process occurs naturally when UV radiation damages DNA in keratinocytes, triggering α-MSH release. MT-II simply bypasses the UV damage step — it directly stimulates melanocytes without requiring any sun exposure at all (Hadley & Dorr, 2006).

However, UV exposure dramatically accelerates and deepens the tan. Most users combine MT-II with modest sun exposure or tanning bed sessions to achieve maximum pigmentation in the shortest time.

The Libido Mechanism

MC4R activation in the hypothalamus (paraventricular nucleus and medial preoptic area) triggers:

• Increased dopamine release in mesolimbic reward circuits
• Enhanced oxytocin signaling
• Activation of descending spinal pathways to genital vasculature
• In males: spontaneous erections, increased sexual thoughts
• In females: genital vasocongestion, increased desire

This is the same mechanism exploited by PT-141 (bremelanotide) — in fact, PT-141 was developed by isolating MT-II's sexual effects into a more selective compound (see comparison section below).

The Appetite Mechanism

MC3R and MC4R activation in the arcuate nucleus of the hypothalamus suppresses orexigenic (hunger-promoting) signaling through:

• Inhibition of NPY/AgRP neurons (hunger signals)
• Enhancement of POMC/CART neurons (satiety signals)
• Reduced ghrelin sensitivity
• Modest increase in metabolic rate

Many users report significant appetite suppression during MT-II loading — eating becomes something you do by schedule rather than hunger cue (Fan et al., 1997).

---

Dosing Protocol: Loading and Maintenance

The Loading Phase

The loading phase establishes a base level of melanin stimulation in melanocytes. Without loading, tanning response is slow and inconsistent.

Standard loading protocol:

• Dose: 250mcg (0.25mg) per day
• Duration: 5-10 days (skin-type dependent)
• Timing: Evening dosing (sleep through nausea)
• Sun exposure: 15-20 minutes moderate UV exposure 3-5x per week during loading
• Starting skin type affects loading duration:
  • Type I (very fair, always burns): 7-10 days loading
  • Type II (fair, usually burns): 5-7 days loading
  • Type III (medium, sometimes burns): 3-5 days loading
  • Types IV-VI: generally do not need MT-II

The Maintenance Phase

Once desired tan is achieved, frequency is reduced dramatically:

• Dose: 250mcg every 3-7 days
• Sun exposure: Brief UV sessions (10-15 minutes) once or twice per week
• Duration: As long as tan maintenance is desired
• Seasonal consideration: Canadian users may maintain year-round with weekly dosing even during winter months with minimal/no UV

Advanced Loading (For Very Fair-Skinned Individuals)

Some Fitzpatrick Type I/II users find 250mcg insufficient:

• Start at 100mcg for 2-3 days (assess nausea tolerance)
• Increase to 250mcg for days 4-7
• If response is minimal after 7 days, increase to 500mcg for days 8-14
• Maximum recommended dose: 500mcg/day (higher doses increase side effects without proportional tanning benefit)
• Total loading may take 2-3 weeks for very fair individuals

Injection Technique

• Reconstitute MT-II with bacteriostatic water (2mL per 10mg vial = 5mg/mL)
• For 250mcg dose: draw 0.05mL (5 units on an insulin syringe)
• Inject subcutaneously (abdomen, thigh, or deltoid fat pad)
• Rotate injection sites
• Evening dosing recommended (nausea peaks 20-40 minutes post-injection — sleeping through it is optimal)

[Internal Link: /bacteriostatic-water/] [Internal Link: /insulin-syringes/]

---

What to Expect: Timeline of Effects

Days 1-3

• Nausea (most common side effect, worst during early loading)
• Possible facial flushing
• Some users notice appetite suppression immediately
• Libido increase may begin (especially in men)
• No visible tanning yet

Days 3-7

• Nausea typically diminishes significantly
• Existing freckles and moles begin darkening (first visible pigmentation change)
• Face and forearms may show slight color shift
• Appetite suppression well-established
• Libido effects pronounced in most users

Days 7-14

• Visible tan developing (especially in sun-exposed areas)
• Tan deepens with each UV exposure session
• Facial pigmentation often leads body (face has higher melanocyte density)
• Side effects largely subsided
• Some users notice skin appears "golden" rather than orange/red (natural melanin vs UV damage pigmentation)

Weeks 3-6

• Full tan expression
• Even very fair individuals can achieve moderate-dark tan
• Transition to maintenance dosing
• Tan quality distinct from pure UV tan (melanin-based rather than inflammation-based)

Maintenance Phase (Ongoing)

• Weekly or bi-weekly dosing maintains color
• Brief UV exposure maintains activation of primed melanocytes
• Color can be maintained indefinitely with consistent protocol
• Some users maintain year-round tans in Canadian winters with just weekly dosing + tanning bed sessions

---

Side Effects: Complete Profile

Common Side Effects (>10% of Users)

Nausea

• Incidence: 40-60% of users during loading
• Timing: 15-45 minutes post-injection, lasting 30-90 minutes
• Severity: Mild-moderate in most; some users experience vomiting
• Management: Evening dosing (sleep through it), ginger 1g pre-dose, start at 100mcg and titrate up, antihistamines (Gravol) for severe cases
• Course: Almost always diminishes by day 4-5 of loading

Facial Flushing

• Incidence: 20-30%
• Timing: 10-30 minutes post-injection, lasting 1-2 hours
• Mechanism: Peripheral vasodilation via melanocortin activation
• Management: Self-resolving; not medically concerning

Appetite Suppression

• Incidence: 50-70% (considered a "side effect" or "benefit" depending on goals)
• Duration: Present throughout active dosing period
• Magnitude: Moderate (not extreme — users can still eat, but hunger cues are blunted)

Libido Increase

• Incidence: 60-80% (more prominent in males)
• Can include spontaneous erections in men, increased genital sensitivity in women
• Duration: Present during active dosing, diminishes when discontinued

Moderate Side Effects (1-10% of Users)

Mole/Freckle Darkening

• This is the most clinically important side effect to monitor
• MC1R activation does not distinguish between melanocytes in clear skin and melanocytes in moles/nevi
• Existing moles will darken — this is expected and usually reversible upon discontinuation
• New moles/freckles may appear
• Critical safety measure: Have a dermatologist photograph and map all moles BEFORE starting MT-II. Repeat every 6-12 months during use. Changes in shape, border irregularity, or asymmetry require immediate dermatological evaluation

Injection Site Soreness

• Mild, localized discomfort at injection site
• Managed by rotating sites and warming solution to room temperature before injection

Fatigue/Lethargy

• Some users report tiredness on injection days (especially during loading)
• May be related to vasodilation and blood pressure changes
• Evening dosing minimizes impact on daily function

Rare Side Effects (<1% of Users)

Significant Darkening of Genital Skin

• Melanocytes in genital tissue respond to MC1R stimulation
• Labia, scrotum, and areolae may darken noticeably
• Reversible upon discontinuation (may take several months)

Periorbital Darkening

• Dark circles under eyes
• May persist longer than body tan after discontinuation

Stomach Cramps

• Occasionally reported beyond simple nausea
• Usually resolves with dose reduction

---

The Mole Question: Safety Considerations

The relationship between Melanotan II and melanoma is the most important safety consideration for any user. Here is what the evidence shows:

What MT-II Does to Moles

• Darkens existing moles (more melanin production in nevus melanocytes)
• May increase mole count (activation of dormant melanocytes)
• Creates pigmented lesions that can mimic dysplastic nevi on dermatoscopy

What MT-II Does NOT Do (Based on Available Evidence)

• No evidence that MT-II causes melanoma in previously normal skin
• No large-scale epidemiological data linking MT-II use to melanoma incidence
• The compound stimulates melanin production — it does not cause malignant transformation

The Nuanced Reality

• If a pre-existing nevus is already on the path to malignant transformation, enhanced melanocyte proliferation could theoretically accelerate that process (Langan et al., 2009)
• MT-II makes surveillance harder (all moles darken, making it difficult to identify the one changing suspiciously)
• The absence of evidence is not evidence of absence — long-term safety data in large populations does not exist

Mandatory Safety Protocol

1. Baseline dermatology visit: Full-body mole mapping before starting MT-II
2. Self-monitoring: Photograph moles monthly. Apply ABCDE criteria (Asymmetry, Border, Color, Diameter, Evolution)
3. Annual dermatology check: Professional dermatoscopic examination at minimum yearly during use
4. Immediate action threshold: Any mole that changes shape, develops irregular borders, becomes multi-colored, grows rapidly, or bleeds → dermatologist within 2 weeks
5. Personal risk assessment: Individuals with family history of melanoma, atypical mole syndrome, or >50 moles should exercise extreme caution or avoid MT-II entirely

---

Storage and Stability

MT-II is relatively fragile compared to many peptides. Proper storage is essential:

Unreconstituted (Lyophilized Powder)

• Ideal: Refrigerated (2-8°C), protected from light
• Acceptable: Room temperature for up to 3 months if sealed and protected from light
• Freezer: Extended storage (years) possible at -20°C
• Light sensitivity: The peptide degrades when exposed to UV and visible light. Keep vials in original packaging or wrapped in foil.

Reconstituted (In Bacteriostatic Water)

• Mandatory: Refrigerated (2-8°C)
• Maximum usable duration: 4-6 weeks
• Light protection: Store in foil wrap or opaque container
• Signs of degradation: Color change (clear → yellow/brown), particulate matter, reduced efficacy

Canadian Climate Considerations

• Summer shipping: Ensure cold-pack delivery; MT-II should not sit in a mailbox at 35°C
• Winter storage: Do not allow reconstituted MT-II to freeze (damages protein structure)
• Travel: Transport in insulated bag with cold pack; do not leave in car (temperature extremes in both seasons)

---

Melanotan II vs. Melanotan I (Afamelanotide): Key Differences

Melanotan I (also called afamelanotide, brand name Scenesse) is a linear analog of α-MSH that is far more selective than MT-II:

When to Choose MT-I Over MT-II

• You want tanning ONLY without libido/appetite effects
• You are concerned about MC4R-mediated side effects
• You have a history of inappropriate erections (MT-II problematic in social situations)
• You want to eat normally during tanning protocol
• You are female and the libido increase of MT-II is unwanted

When MT-II Is Preferred

• You want the multi-benefit profile (tanning + libido + appetite control)
• You are on a cut/prep and the appetite suppression is welcome
• The libido enhancement is desired
• Budget is a factor (MT-II is significantly cheaper)
• You want a well-established community protocol with extensive user experience data

---

Combining MT-II with Training Goals

Contest Prep / Cutting Phase

MT-II is popular during bodybuilding contest prep for multiple synergistic reasons:

• Appetite suppression helps adherence to caloric deficit
• Tan makes muscle definition appear more pronounced on stage
• Does not interfere with other contest prep compounds
• Can reduce the need for excessive tanning bed sessions (UV damage/aging concern)

Bulking Phase

Less ideal due to appetite suppression, but some users:

• Dose only 1-2x/week (maintains tan without heavy appetite suppression)
• Time doses on rest days when appetite demands are lower
• Accept the mild appetite blunting as a trade-off for year-round color

General Fitness / Aesthetic Goals

Many non-competitive users employ MT-II simply for:

• Year-round healthy color (especially relevant in Canada, October-April)
• Reduced UV exposure needed for tanning (less skin aging, less cancer risk per unit of tan)
• The confidence boost of appearing tanned and lean
• Anti-aging benefit of less cumulative UV damage over a lifetime

---

Frequently Asked Questions

Can I get a tan from Melanotan II without any sun exposure?

Technically yes — MT-II stimulates melanin production regardless of UV exposure. However, the tan will be very gradual, uneven, and take significantly longer to develop without UV activation. UV light (sun or tanning bed) stimulates melanocyte activity synergistically with MT-II, and distributes the tan more evenly. Most protocols recommend 15-20 minutes of moderate sun exposure 3-5 times per week during loading, and 1-2 brief sessions per week during maintenance. Even brief UV exposure (10 minutes) dramatically accelerates results.

How long does the tan last after stopping Melanotan II?

Without continued MT-II administration, the tan fades through natural skin turnover (the epidermis replaces itself approximately every 28-40 days). Most users report visible fading within 2-3 weeks of stopping, with color returning to baseline within 4-8 weeks depending on initial depth of tan and continued sun exposure. Some users with naturally olive/medium skin may retain slight residual color longer, as their melanocytes were already primed. Winter fading is faster (no incidental UV to maintain melanocyte activity).

Is Melanotan II safe for dark-skinned individuals?

Individuals with Fitzpatrick Type IV-VI skin (naturally brown to very dark) generally do not need MT-II — their melanocytes are already producing eumelanin abundantly. Using MT-II in darker-skinned individuals can produce hyperpigmentation in certain areas (patches of significantly darker skin), uneven pigmentation, and very dark mole development. It is not recommended for those who already tan easily and deeply, as the risk-to-benefit ratio is poor. The compound was designed for and is most appropriate for fair-skinned (Type I-III) individuals.

Will Melanotan II protect me from sunburn?

To some degree, yes. Melanin is the skin's natural UV protector — it absorbs UV radiation and dissipates it as heat, preventing DNA damage in keratinocytes. MT-II-induced melanin provides real photoprotection, estimated at SPF 3-6 depending on tan depth (Barnetson et al., 2006). However, this is NOT a substitute for sunscreen. Fair-skinned users with a MT-II tan are more protected than they would be without it, but can still burn with extended UV exposure. Continue using SPF 30+ for prolonged outdoor activity.

Can I use Melanotan II if I have a history of melanoma?

This is a personal risk decision that should involve your dermatologist. The conservative recommendation is NO — stimulating melanocyte proliferation in someone with a history of melanoma (meaning their melanocytes have demonstrated capacity for malignant transformation) carries theoretical risk of stimulating dormant or residual malignant cells. There is no clinical evidence directly linking MT-II to melanoma recurrence, but absence of evidence ≠ evidence of safety. If you have personal melanoma history, the risk-benefit calculation strongly favors avoiding MT-II.

---

Reconstitution and Preparation Guide

What You Need

• Melanotan II 10mg lyophilized vial
• Bacteriostatic water (BAC water)
• Insulin syringes (0.5mL or 1mL, 29-31 gauge)
• Alcohol swabs
• Refrigerator for storage

Step-by-Step Reconstitution

1. Allow MT-II vial and BAC water to reach room temperature (15 minutes)
2. Wipe both vial stoppers with alcohol swab
3. Draw 2mL bacteriostatic water into syringe (this creates 5mg/mL concentration)
4. Insert needle through MT-II vial stopper at an angle
5. Release water SLOWLY down the inside wall of the vial — do NOT spray directly onto powder
6. Allow powder to dissolve naturally (2-5 minutes) — do NOT shake
7. Gently roll vial between palms if any powder remains undissolved
8. Solution should be clear and colorless
9. Label vial with date of reconstitution
10. Store immediately in refrigerator, wrapped in foil

Dosing Math

With 10mg vial reconstituted in 2mL:

• Concentration: 5mg/mL (5000mcg/mL)
• 250mcg dose = 0.05mL = 5 units on a 100-unit insulin syringe
• 500mcg dose = 0.10mL = 10 units
• 100mcg dose = 0.02mL = 2 units

Common Reconstitution Mistakes

• Spraying water directly on powder (causes foaming and potential denaturation)
• Shaking vial (damages protein structure)
• Using sterile water instead of bacteriostatic water (no preservative = bacterial growth)
• Reconstituting with too much water (makes accurate small-dose measurement difficult)
• Storing at room temperature after reconstitution (peptide degrades rapidly)

[Internal Link: /bacteriostatic-water/]

---

Legal and Regulatory Status in Canada

Melanotan II occupies a regulatory grey zone in Canada:

• Not approved by Health Canada for any indication
• Not classified as a controlled substance
• Not explicitly banned for personal possession
• Available from Canadian research peptide suppliers
• Cannot be legally marketed as a consumer product with health claims
• Importation for personal use is generally not intercepted by CBSA

Canadian users should understand that:

• No physician will prescribe MT-II (not in any formulary)
• Product quality varies between suppliers (third-party testing recommended)
• Using MT-II is an informed personal decision with inherent risk acceptance
• The compound is explicitly banned in some other jurisdictions (e.g., Norwegian drug laws classify it)

---

Conclusion

Melanotan II offers a unique pharmacological proposition: melanin-based tanning with reduced UV dependence, pronounced libido enhancement, and moderate appetite suppression — all from a single daily 250mcg injection. For fair-skinned Canadians facing six months of minimal sun, the appeal is obvious. A year-round tan without excessive UV exposure means less photoaging, less cumulative skin cancer risk per unit of color achieved, and the aesthetic and psychological benefits of appearing healthy and bronzed.

But the compound demands respect. The mole-darkening effect requires active dermatological surveillance. The multi-receptor activation means you accept the full constellation of effects, not just the one you want. And the absence of long-term safety data in large populations means every user is, to some degree, an informed volunteer in an ongoing observational study.

For those who decide to proceed: start at 250mcg, dose in the evening, expect and manage the initial nausea, get your moles mapped before starting, combine with modest UV exposure for optimal results, and transition to maintenance dosing once you achieve your desired shade. The compound works. The question is not efficacy — it is whether you accept the risk profile given your individual circumstances.

[Internal Link: /melanotan-2/] [Internal Link: /bacteriostatic-water/] [Internal Link: /insulin-syringes/]

---

Disclaimer: This article is for educational and harm-reduction purposes only. Melanotan II is not approved for human use by Health Canada or any major regulatory agency. It carries potential health risks. Consult a healthcare professional and dermatologist before using any tanning peptides.

References:

1. Hadley, M.E. & Dorr, R.T. (2006). Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides, 27(4), 921-930. PubMed: 16412534
2. Fan, W., et al. (1997). Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature, 385(6612), 165-168. PubMed: 8990120
3. Barnetson, R.S., et al. (2006). [Nle4-D-Phe7]-α-melanocyte-stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers. Journal of Investigative Dermatology, 126(8), 1869-1878. PubMed: 16763547
4. Langan, E.A., et al. (2009). Darkening of a melanocytic lesion during use of Melanotan II. British Journal of Dermatology, 161(1), 173-175.
5. Wessells, H., et al. (2000). Effect of an α-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology, 56(4), 641-646. PubMed: 11018622
6. Dorr, R.T., et al. (1996). Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers. Archives of Dermatology, 132(3), 272-278. PubMed: 8607630
7. Hruby, V.J., et al. (2011). Melanocortin receptors: their biology and roles in disease and therapeutic potential. Expert Reviews in Endocrinology & Metabolism, 6(5), 735-749.
8. Nelson, M.E., et al. (2012). Melanotan II use among men in a general population survey. Drug and Alcohol Review, 31(7), 907-911. PubMed: 22524456
9. Reid, C. & Fitzgerald, T. (2010). Melanotan II use reported in a sunbed user. British Medical Journal, 340, c2014.